Stopping a GLP-1: what the evidence says about plateaus and weight regain

This page is for people who want to understand what the evidence shows about plateaus and stopping a GLP-1 medication, so they can ask their clinician better questions.

It is not a how-to for stopping, and it is not a recommendation either way. If you are wrestling with cost, side effects, or long-term plans, those are exactly the things to raise with your prescriber, who can help you weigh the options for your situation.

Most people on a GLP-1 medication reach a point where weight loss slows and then levels off. In the pivotal trials, average weight tended to decline over roughly the first year and then stabilize, which reflects the body reaching a new balance rather than the medication failing.

A plateau is expected physiology, not necessarily a sign that anything is wrong. Whether to adjust anything at that point, dose, diet, activity, or expectations, is a clinical conversation. It is worth remembering that maintaining a significant loss is itself a meaningful outcome, even when the scale stops moving.

The clearest evidence on stopping comes from an extension of the STEP 1 trial of semaglutide. After participants stopped the medication and the lifestyle intervention, they regained a large portion of the weight they had lost over the following year, and many cardiometabolic improvements moved back toward their starting values.

The interpretation researchers draw is that obesity behaves like a chronic condition: for many people these medications manage weight while taken, rather than curing the underlying biology. That does not mean stopping is wrong for any given person; it means the likely trajectory after stopping is something to plan for with a clinician, not to discover by surprise.

The SURMOUNT-4 trial tested this more directly with tirzepatide. After an initial lead-in period on the medication, participants were randomized either to continue tirzepatide or to switch to placebo. Those who continued kept losing or maintained their weight loss, while those switched to placebo regained a substantial portion of it.

Together with the STEP 1 extension, this points in the same direction across two different medications: continued treatment supports maintained weight loss, and stopping is commonly followed by regain. This is trial-average behavior, and individual experiences vary, which is one more reason the decision belongs in a clinical setting.

Whatever you and your clinician decide, the lifestyle foundation still matters. Adequate protein and resistance training help protect muscle whether you are losing, maintaining, or navigating a change in medication, since muscle preserved during treatment is muscle you keep afterward.

There is no supplement shown to prevent weight regain after stopping a GLP-1, and it would be misleading to suggest otherwise. The honest levers are the familiar ones, nutrition, activity, sleep, and ongoing medical support, and any plan to stop is safest when it is deliberate and clinician-guided rather than abrupt and solo.

Deciding whether to continue, pause, or stop a GLP-1 involves your diabetes status, cardiovascular risk, other medications, cost, side effects, and personal goals. That is far more than any general article can weigh, which is exactly why the decision sits with your prescribing clinician.

If cost, side effects, or long-term concerns are pushing you toward stopping, bring those directly to your prescriber. There may be options, such as adjusting dose or timing or planning a maintenance approach, that are not obvious from the outside. Please do not change your medication based on anything on this page.